Get the Stockscreener App
0.00
100.00%
-0.9347
Homology Medicines Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9357 pivot point. If it approaches the $0.8265 support level, significant changes may occur.
Previous Close:
$0.9347
Open:
$0
24h Volume:
0
Market Cap:
$3.02M
Revenue:
$2.76M
Net Income/Loss:
$-112.96M
P/E Ratio:
0.00
EPS:
-2.3
Net Cash Flow:
$-96.46M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1D Range:
$0.00
$0.00
52W Range:
$0.00
$1.48
Homology Medicines Inc Stock (FIXX) Company Profile
Name
Homology Medicines Inc
Sector
Industry
Phone
781 301 7277
Address
One Patriots Park, Bedford
Homology Medicines Inc Stock (FIXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-20-19 | Initiated | H.C. Wainwright | Buy |
| Jan-07-19 | Initiated | Canaccord Genuity | Buy |
| Sep-07-18 | Initiated | B. Riley FBR | Neutral |
View All
Homology Medicines Inc Stock (FIXX) Latest News
Homology Medicines Declares Distribution to Common Stockholders
GlobeNewswire Inc.
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire Inc.
Gold Gains 1%; Williams-Sonoma Posts Upbeat Earnings
Benzinga
Why Children's Place Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Crude Oil Down 4%; Walmart Shares Fall After Q3 Results
Benzinga
Q32 Bio and Homology Medicines Announce Merger Agreement
GlobeNewswire Inc.
Homology Medicines Inc Stock (FIXX) Financials Data
Homology Medicines Inc (FIXX) Revenue 2024
FIXX reported a revenue (TTM) of $2.76 million for the quarter ending June 30, 2023, a -32.40% decline year-over-year.
Homology Medicines Inc (FIXX) Net Income 2024
FIXX net income (TTM) was -$112.96 million for the quarter ending December 31, 2023, a -2,157% decrease year-over-year.
Homology Medicines Inc (FIXX) Cash Flow 2024
FIXX recorded a free cash flow (TTM) of -$96.46 million for the quarter ending December 31, 2023, a +16.08% increase year-over-year.
Homology Medicines Inc (FIXX) Earnings per Share 2024
FIXX earnings per share (TTM) was -$35.10 for the quarter ending December 31, 2023, a -1,673% decline year-over-year.
Homology Medicines Inc Stock (FIXX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Michaud Charles Jr | See Remarks |
Mar 25 '24 |
Sale |
24.20 |
75 |
1,815 |
927 |
| TZIANABOS ARTHUR | Director |
Jan 09 '24 |
Sale |
0.57 |
13,037 |
7,445 |
128,778 |
| Alloway Paul | See Remarks |
Jan 03 '24 |
Sale |
0.57 |
7,280 |
4,120 |
28,036 |
| Michaud Charles Jr | See Remarks |
Jan 03 '24 |
Sale |
0.57 |
1,708 |
975 |
11,598 |
| Seymour Albert | See Remarks |
Sep 06 '23 |
Sale |
1.15 |
1,448 |
1,665 |
150,874 |
| Jordan Julie | Chief Medical Officer |
Aug 03 '23 |
Option Exercise |
0.00 |
6,579 |
0 |
8,804 |
| Jordan Julie | Chief Medical Officer |
Aug 03 '23 |
Sale |
1.39 |
1,853 |
2,576 |
3,882 |
| Jordan Julie | Chief Medical Officer |
Aug 02 '23 |
Option Exercise |
0.00 |
350 |
0 |
2,869 |
| Jordan Julie | Chief Medical Officer |
Aug 02 '23 |
Sale |
1.31 |
99 |
130 |
2,770 |
About Homology Medicines Inc
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
1.47%
1.73%
Cap:
|
Volume (24h):